AQST Aquestive Therapeutics, Inc.companySEC Filings & Insider Trading Activity 2026
Latest Aquestive Therapeutics, Inc. (AQST) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on March 4, 2026, a 10-Q quarterly report filed on November 5, 2025, an 8-K current report filed on March 30, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Aquestive Therapeutics, Inc. (AQST) (SEC CIK 1398733), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 7.01: Regulation FD Disclosure
- • Aquestive (AQST) releasing updated investor presentation to institutional investors and analysts — potential catalyst for institutional interest
- • Presentation filed as Exhibit 99.2; full content of disclosed information resides there
Item 2.02: Results of Operations and Financial Condition
- • Q4 and full-year fiscal 2025 earnings reported; period ended December 31, 2025
- • Full financial details and schedules in Exhibit 99.1 of this 8-K filing
Item 1.01: Entry into a Material Definitive Agreement
- • Marketing Approval Deadline for RTW Purchase and Sale Agreement extended to June 30, 2027, buying more time for regulatory milestone
- • RTW receives warrant for 375,000 shares at $4.00/share, expiring March 3, 2029 — dilution cost for the extension
Recent 8-K FilingsCurrent Reports
AI-powered analysis of Aquestive Therapeutics, Inc. (AQST) 8-K current reports disclosing material events.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Mar 30, 2026 | — | — | — |
8-K | Mar 20, 2026 | — | — | — |
10-K | Mar 4, 2026 | Dec 31, 2025 | — | |
8-K | Mar 4, 2026 | — | Analysis | — |
8-K | Feb 26, 2026 | — | Analysis | — |
8-K | Feb 2, 2026 | — | — | |
8-K | Jan 9, 2026 | — | — | |
10-Q | Nov 5, 2025 | Sep 30, 2025 | — | |
10-Q | Aug 11, 2025 | Jun 30, 2025 | — | |
10-Q | May 12, 2025 | Mar 31, 2025 | — | |
10-K | Mar 5, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 4, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 6, 2024 | Jun 30, 2024 | — | |
10-Q | May 7, 2024 | Mar 31, 2024 | — | |
10-K | Mar 5, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 6, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 7, 2023 | Jun 30, 2023 | — | |
10-Q | May 2, 2023 | Mar 31, 2023 | — | |
10-K | Mar 31, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 1, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 2, 2022 | Jun 30, 2022 | — | |
10-Q | May 4, 2022 | Mar 31, 2022 | — | |
10-K | Mar 8, 2022 | Dec 31, 2021 | — | |
10-Q | Nov 2, 2021 | Sep 30, 2021 | — | |
10-Q | Aug 3, 2021 | Jun 30, 2021 | — |
Frequently Asked Questions
What are the latest AQST SEC filings in 2026?
Aquestive Therapeutics, Inc. (AQST) has filed a 10-K annual report on March 4, 2026, a 10-Q quarterly report on November 5, 2025, an 8-K current report on March 30, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did AQST file its most recent 10-K annual report?
Aquestive Therapeutics, Inc. (AQST) filed its most recent 10-K annual report on March 4, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view AQST 10-Q quarterly reports?
Aquestive Therapeutics, Inc. (AQST)'s most recent 10-Q quarterly report was filed on November 5, 2025. SignalX displays every AQST 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has AQST filed recently?
Aquestive Therapeutics, Inc. (AQST)'s most recent 8-K was filed on March 30, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find AQST insider trading activity (Form 4)?
SignalX aggregates every AQST Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does AQST file with the SEC?
Aquestive Therapeutics, Inc. (AQST) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new AQST filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Aquestive Therapeutics, Inc. (AQST).
What is AQST's SEC CIK number?
Aquestive Therapeutics, Inc. (AQST)'s SEC CIK (Central Index Key) number is 1398733. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1398733 to look up all AQST filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find AQST return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from Aquestive Therapeutics, Inc. (AQST) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of Aquestive Therapeutics, Inc. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 37+ filings.